- $99.56m
- $40.32m
- $237.26m
Vaxart Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Vaxart Appoints Jeroen Grasman As Chief Financial Officer
Brief: Vaxart Q1 Net Income USD -15.591 Million
Vaxart Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Vaxart Completes Enrollment In Phase 1 Trial For Its Norovirus Oral Pill Vaccine Candidate
Brief: Vaxart Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Vaxart Inc to offer up to $50 mln of common stock
Vaxart Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Vaxart Provides Business Update And Reports Full Year 2024 Financial Results
Vaxart Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Vaxart starts early-stage study for its pill-based vaccine for norovirus
Vaxart Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Vaxart Completes Enrollment Of Sentinel Cohort In Phase 2B Study
Brief: Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Vaxart Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Vaxart Q3 Net Income USD -14.08 Million
Vaxart Inc expected to post a loss of 10 cents a share - Earnings Preview
Vaxart Inc expected to post a loss of 10 cents a share - Earnings Preview
Vaxart Inc expected to post a loss of 10 cents a share - Earnings Preview